Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg upgrades Energean to 'buy'

(Sharecast News) - Analysts at Berenberg upgraded exploration and production outfit Energean from 'hold' to 'buy' on Tuesday, stating the group appeared to be "resilient" to current market volatility. Berenberg said it had updated its model on Energean to reincorporate its Egyptian, Italian and Croatian assets that were part of the disposal process to Carlyle. It also reduce its 2025 price deck in line with the rest of its coverage.

Importantly, Berenberg noted that only 20% of Energean's production was exposed to spot pricing, insulating the company from short-term commodity price volatility.

In its view, adding back the disposal assets improved near-term cash flow and dividend capacity in the business, although it acknowledged that Energean's $200.0m special dividend will now probably not be paid.

The German bank stated the net effect of its modelling changes had led to an increased price target of 1,000.0p, up from 940.0p, and more scope for "sustainable growth in shareholder returns".

"Adding back the disposal assets increases our 2025 and 2026 production forecasts by 36% and 28% respectively. The higher revenue drives EBITDA forecasts which are up 57% and 36% versus our previous numbers, and our EPS forecasts are now 138% and 83% higher than previously," said Berenberg.

"On our updated forecasts, the shares are trading on 2025/26 EV/EBITDA of 3.6x/3.4x, EV/DACF of 4.1x/3.8x and FCFE yield of 16%/20% and a dividend yield of 12%/14%."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.